Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29–41
CAS
Article
PubMed
Google Scholar
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61–67
CAS
Article
PubMed
Google Scholar
De Herder WW (2016) The history of acromegaly. Neuroendocrinology 103:7–17
Article
PubMed
Google Scholar
Chanson P, Salenave S (2008) Acromegaly. Orphanet J Rare Dis 3:17
Article
PubMed
PubMed Central
Google Scholar
Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797
CAS
PubMed
Google Scholar
Veldhuis JD, Erickson D, Iranmanesh A, Miles JM, Bowers CY (2005) Sex-steroid control of the aging somatotropic axis. Endocrinol Metab Clin N Am 34:877–893
CAS
Article
Google Scholar
Roelfsema F, Veldhuis JD (2016) Growth hormone dynamics in healthy adults are related to age and sex and strongly dependent on body mass index. Neuroendocrinology 103:335–344
CAS
Article
PubMed
Google Scholar
Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951
CAS
Article
PubMed
Google Scholar
Katznelson L, Atkinson JLD (2011) AACE guidelines for the diagnosis and treatment of acromegaly. Endocr Pract 17:1–44
Article
PubMed
Google Scholar
Rosario PW (2010) Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metab 54:477–481
Article
Google Scholar
Guven B, Can M, Mungan G, Acіkgoz S (2013) Reference values for serum levels of insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3) in the West Black Sea region of Turkey. Scand J Clin Lab Invest 73:135–140
CAS
Article
PubMed
Google Scholar
Roelfsema F, Biermasz NR, Pereira AM, Veldhuis JD (2016) Optimizing blood sampling protocols in patients with acromegaly for the estimation of growth hormone secretion. J Clin Endocrinol Metab 101:2675–2682
CAS
Article
PubMed
Google Scholar
Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ, van der Lely AJ, de Herder WW (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90:6480–6489
CAS
Article
PubMed
Google Scholar
Haidich AB (2010) Meta-analysis in medical research. Hippokratia 14:29–37
CAS
PubMed
PubMed Central
Google Scholar
Schilbach K, Strasburger CJ, Bidlingmaier M (2017) Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20:33–45
CAS
Article
PubMed
Google Scholar
Danhof M (2015) Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. J Pharmacokinet Pharmacodyn 42:447–462
CAS
Article
PubMed
PubMed Central
Google Scholar
Pokrajac A, Claridge AG, Shakoor SKA, Trainer PJ (2006) The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154:267–274
CAS
Article
PubMed
Google Scholar
Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW (1992) The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. YALE J Biol Med 65:505–518
CAS
PubMed
PubMed Central
Google Scholar
Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ (2013) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxford) 79:689–699
CAS
Google Scholar
Garrido MJ, Cendrós J-M, Ramis J, Peraire C, Obach R, Trocóniz IF (2012) Pharmacodynamic modeling of the effects of lanreotide autogel on growth hormone and insulin-like growth factor 1. J Clin Pharmacol 52:487–498
CAS
Article
PubMed
Google Scholar
Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P, Maffezzoni F, Montini M, Terzolo M, Ghigo E (2017) High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab 102:2454–2464
Article
PubMed
Google Scholar
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A (2014) Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol 54:1308–1317
CAS
Article
PubMed
Google Scholar
Neggers SJCMM, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, Gadelha MR, Maisonobe P, Sert C, Van Der Lely AJ (2015) Lanreotide autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol 173:313–323
CAS
Article
PubMed
PubMed Central
Google Scholar
Fahlbusch R et al (2017) Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly. Pituitary 20:668–675
CAS
Article
PubMed
Google Scholar
Casagrande A, Bronstein MD, Jallad RS, Mota JI, Tabet A, Abucham J (2017) Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study. J Endocrinol Invest 40:523–528
CAS
Article
PubMed
Google Scholar
Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y, Bronstein MD (2015) Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. Eur J Endocrinol 172:707–713
CAS
Article
PubMed
Google Scholar
Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM (2014) Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol 171:229–235
CAS
Article
PubMed
Google Scholar
Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M (2015) Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center. Pituitary 18:290–296
CAS
Article
PubMed
Google Scholar
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, Maisonobe P, Clermont A (2014) Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99:1282–1290
CAS
Article
PubMed
Google Scholar
Vilar L, Fleseriu M, Naves LA, Albuquerque JL, Gadelha PS, Dos Santos Faria M, Nascimento GC, Montenegro RM, Montenegro RM (2014) Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? results from a multicenter prospective trial. Endocrine 46:577–584
CAS
PubMed
Google Scholar
Dias M, Bouszewski C, Gadelha M, Kasuki L, Musolino N, Vieira JGH, Abucham J (2014) Acromegaly and pregnancy: a prospective study. Eur J Endocrinol 170:301–310
CAS
Article
PubMed
Google Scholar
Annamalai AK et al (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98:1040–1050
CAS
Article
PubMed
Google Scholar
Li Z-Q, Quan Z, Tian H-L, Cheng M (2012) Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 40:517–524
CAS
Article
PubMed
Google Scholar
Melmed S et al (2015) Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 100:1699–1708
CAS
Article
PubMed
Google Scholar
Gadelha M, Chieffo C, Bai S, Hu X, Frohman L (2012) A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Endocr Pract 18:870–881
Article
PubMed
Google Scholar
Chieffo C, Cook D, Xiang Q, Frohman LA (2013) Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 98:jc.2013–2262
Article
Google Scholar
Tahara S, Murakami M, Kaneko T, Shimatsu A (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64:735–747
Article
PubMed
Google Scholar
Khairi S, Sagvand BT, Pulaski-Liebert KJ, Tritos NA, Klibanski A, Nachtigall LB (2017) Clinical outcomes and self-reported symptoms in patients with acromegaly: an 8-year follow-up of a lanreotide study. Endocr Pract 23:56–65
Article
PubMed
Google Scholar
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen C-C, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P (2016) Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocr Disord 16:16
Article
PubMed
PubMed Central
Google Scholar
Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, Pedroncelli AM, Fleseriu M (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53:210–219
CAS
Article
PubMed
PubMed Central
Google Scholar
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabet Endocrinol 2:875–884
CAS
Article
Google Scholar
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen YM, Colao A (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18:385–394
CAS
Article
PubMed
Google Scholar
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, Van Der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791–799
CAS
Article
PubMed
PubMed Central
Google Scholar
Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K (2013) Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J 60:651–663
CAS
Article
PubMed
Google Scholar
Ramirez C, Vargas G, González B, Grossman A, Rábago J, Sosa E, Espinosa-de-Los-Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21–26
CAS
Article
PubMed
Google Scholar
Petersenn S, Farrall AJ, Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A (2014) Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17:132–140
CAS
Article
PubMed
Google Scholar
Velija-Asimi Z (2012) The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy. Ther Adv Endocrinol Metab 3:3–9
CAS
Article
PubMed
PubMed Central
Google Scholar
Gheorghiu ML, Găloiu S, Vintilă M, Purice M, Hortopan D, Dumitraşcu A, Coculescu M, Poiană C (2016) Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center. Hormones 15:224–234
Article
PubMed
Google Scholar
Young Lee S, Hee Kim J, Hyun Lee J, Hwy Kim Y, Jin Cha H, Wan Kim S, Ha Paek S, Soo Shin C (2018) The efficacy of medical treatment in patients with acromegaly in clinical practice. Endocr J 65:33–41
Google Scholar
Salvatori R, Gordon MB, Woodmansee WW, Ioachimescu AG, Carver DW, Mirakhur B, Cox D, Molitch ME (2017) A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary 20:605–618
CAS
Article
PubMed
Google Scholar
Borges M, Lara B, Tomé J, Araújo L, Bugiga F, Sousa J, Soares J, Dezena R, Ferreira B (2017) Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): experience report. Clinics (Sao Paulo) 72:218–223
Article
Google Scholar
Kasuki L, Machado EDO, Ogino LL, Alves Coelho MC, dos Santos Silva CM, Armondi Wildemberg LE, Azeredo Lima CH, Gadelha MR (2016) Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch Endocrinol Metab 60:479–485
Article
PubMed
Google Scholar
Puig-Domingo M et al (2016) Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study | Uso de lanreotida en combinación con cabergolina o pegvisomant en la práctica clínica en pacientes con acromegalia. Endocrinol y Nutr 63:397–408
Article
Google Scholar
Casagrande A et al (2017) Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event. Neuroendocrinology 104:273–279
CAS
Article
PubMed
Google Scholar
Sagvand BT, Khairi S, Haghshenas A, Swearingen B, Tritos NA, Miller KK, Klibanski A, Nachtigall LB (2016) Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary 19:437–447
CAS
Article
PubMed
Google Scholar
Chang JS, Tseng HM, Chang TC (2016) Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. J Formos Med Assoc 115:475–480
CAS
Article
PubMed
Google Scholar
Vandeva S, Elenkova A, Natchev E, Kirilov G, Tcharaktchiev D, Yaneva M, Kalinov K, Marinov M, Hristozov K, Kamenov Z, Orbetzova M, Gerenova J, Tsinlikov I, Zacharieva S (2015) Treatment outcome results from the bulgarian acromegaly database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients. Exp Clin Endocrinol Diabetes 123:66–71
CAS
Article
PubMed
Google Scholar
Evran M, Sert M, Tetiker T (2014) Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients. BMC Endocr Disord 14:97
Article
PubMed
PubMed Central
Google Scholar
Hatipoglu E, Bozcan S, Kadioglu P (2015) Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary 18:554–560
CAS
Article
PubMed
Google Scholar
Mangupli R, Camperos P, Webb SM (2014) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17:495–499
CAS
Article
PubMed
Google Scholar
Sanyal D, Raychaudhuri M (2012) Outcome in acromegaly: a retrospective analysis. Indian J Endocrinol Metab 16:S291-3
PubMed
Google Scholar
Salvatori R, Woodmansee WW, Molitch M, Gordon MB, Lomax KG (2014) Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 17:13–21
CAS
Article
PubMed
Google Scholar
Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, Yamamoto M, Yamada S, Takahashi Y (2013) Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J 60:507–515
CAS
PubMed
Google Scholar
Demir O, Gedik V, Corapcioglu D, Emral R, Unlu MA, Erdogan MF, Gullu S, Uysal AR, Baskal N (2012) Improvement in remission rates of the first operation in acromegalic patients. Turk Neurosurg 22:645–650
PubMed
Google Scholar
Bernabeu I, Alvarez-Escolá C, Paniagua AE, Lucas T, Pavón I, Cabezas-Agrícola JM, Casanueva FF, Marazuela M (2013) Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16:101–108
CAS
Article
PubMed
Google Scholar
Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187–1193
CAS
Article
PubMed
Google Scholar
Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, Aydin Y, Guler S (2012) Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 15:398–404
CAS
Article
PubMed
Google Scholar
Cuneo RC, Hickman PE, Wallace JD, Teh BT, Ward G, Veldhuis JD, Waters MJ (1995) Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol (Oxford) 43:265–275
CAS
Article
Google Scholar
Stalla GK, Ferone D, Colao A (2014) Is clinical practice reflective of acromegaly treatment guidelines? results from a survey of treating physicians in 45 countries. ENDO Annual Meeting
Biermasz NR (2017) New medical therapies on the horizon: oral octreotide. Pituitary 20:149–153
CAS
Article
PubMed
PubMed Central
Google Scholar
PhUSE CSS Development of Standard Scripts for Analysis and Programming Working Group (2014) Analyses and displays associated to non-compartmental pharmacokinetics—with a focus on clinical trials. Retrieved from http://www.phusewiki.org/wiki/images/e/ed/PhUSE_CSS_WhitePaper_PK_final_25March2014.pdf
Motulsky HJ (2014) Common misconceptions about data analysis and statistics. Naunyn Schmiedebergs Arch Pharmacol 387:1017–1023
CAS
Article
PubMed
PubMed Central
Google Scholar
Madadizadeh F, Asar ME, Hosseini M (2015) Common statistical mistakes in descriptive statistics reports of normal and non-normal variables in biomedical sciences research. Iran J Public Health 44:1557–1558
PubMed
PubMed Central
Google Scholar
Ghasemi A, Zahediasl S (2012) Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab 10:486–489
Article
PubMed
PubMed Central
Google Scholar